Recursion Pharmaceuticals
Recursion Pharmaceuticals' revenue rose 26.9% to $75 million in fiscal 2025. Its operating margin was −867.9%, down from −814.1% a year earlier. Free cash flow was −$378 million. The diluted share count rose 63.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Recursion Pharmaceuticals does
Recursion is a drug developer that uses software, machine learning and large amounts of lab data to find new medicines. It calls itself a clinical-stage "TechBio" company, meaning its drug candidates are being tested in people but none has been approved. Its in-house platform, the Recursion Operating System, is meant to map biology, design small molecules and plan clinical trials.
Recursion has no approved products and has not earned revenue from selling a drug. Its income comes from partners that pay it for data and for progress on drug programs, mainly Roche and Genentech and Sanofi. It says it has received over $500 million in partner payments so far, and it is eligible for more milestone payments and royalties if programs advance and become medicines.
The company runs its own pipeline of drug candidates, including one for a rare inherited condition called familial adenomatous polyposis (FAP), which causes growths in the colon. It says it is prioritizing its clinical programs and streamlining operations, and it spends heavily on research and development.
Its biggest risks, as it describes them
- It has no approved products and has lost money since it began, so it needs to raise more funding or cut programs.
- Its drug candidates are in early or mid-stage testing, and trials can fail, be delayed or show safety problems.
- Its AI-based approach to finding drugs is unproven and may not produce successful medicines.
- Raising money by selling more shares could dilute current holders and limit what it can do.
- It depends on partners and outside providers for parts of its work, and on its computing systems.
Income statement
Recursion Pharmaceuticals lost money in fiscal 2025: a net loss of $645 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 517 | 550 | 392 | 594 | 743 |
| Debt incl. finance leases | 1 | 1 | 1 | 27 | 19 |
| Net debt (negative means net cash) | −516 | −549 | −390 | −567 | −725 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −61.9x | −4,467.8x | −3,608.9x | −304.7x | −358.1x |
| Current ratio | 11.5x | 5.7x | 4.7x | 3.8x | 5.5x |
| Quick ratio | 11.5x | 5.7x | 4.7x | 3.8x | 5.5x |
Cash flow
Projections
Project Recursion Pharmaceuticals' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Recursion Pharmaceuticals shares on the open market, and 5 insiders sold $7.1 million, all of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 8, 2026 | Najat KhanCEO and President, Director | Sold plan | 22,408 | $3.52 | $78,876 | Form 4 |
| Sep 1, 2026 | Blake BorgesonDirector | Sold plan | 30,000 | $3.34 | $100,200 | Form 4 |
| Aug 4, 2026 | Blake BorgesonDirector | Sold plan | 30,000 | $3.25 | $97,500 | Form 4 |
| Jul 7, 2026 | Blake BorgesonDirector | Sold plan | 40,000 | $3.96 | $158,400 | Form 4 |
| Jun 18, 2026 | Namandje BumpusDirector | Sold plan | 3,963 | $3.18 | $12,602 | Form 4 |
| Jun 5, 2026 | Christopher GibsonDirector | Sold plan | 40,000 | $3.62 | $144,800 | Form 4 |
| Jun 5, 2026 | Najat KhanCEO and President, Director | Sold plan | 23,588 | $3.58 | $84,445 | Form 4 |
| Jun 3, 2026 | Namandje BumpusDirector | Sold plan | 4,386 | $3.54 | $15,526 | Form 4 |
| Jun 2, 2026 | Blake BorgesonDirector | Sold plan | 30,000 | $3.68 | $110,400 | Form 4 |
| May 22, 2026 | Christopher GibsonDirector | Sold plan | 40,000 | $3.08 | $123,200 | Form 4 |
| May 7, 2026 | Christopher GibsonDirector | Sold plan | 40,000 | $3.37 | $134,800 | Form 4 |
| May 5, 2026 | Blake BorgesonDirector | Sold plan | 30,000 | $3.52 | $105,600 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 9 | 3 of 9 | 4 of 9 |
| Rule of 40 | −660.5% | −601.7% | −479.6% |
| Altman Z'' | −2.40 | −0.43 | −1.13 |
| Accruals ratio | −6.0% | −9.9% | −18.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 2 of 9 | 3 of 9 | 4 of 9 |
Compare
Put Recursion Pharmaceuticals side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals | FY25 | 26.9% | −867.9% | −506.5% | −117.2% | — | 4 | |
| CytomX Therapeutics | FY25 | −44.8% | −29.4% | −99.5% | — | — | — | Compare |
| Vir Biotechnology | FY25 | −7.6% | −699.2% | −578.5% | — | — | — | Compare |
| MeiraGTx | FY25 | 144.6% | −130.2% | −61.7% | — | — | 3 | Compare |
| Intellia Therapeutics | FY25 | 16.9% | −651.7% | −585.0% | — | — | — | Compare |
7 years of figures
| Fiscal year | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 2 | 4 | 10 | 40 | 45 | 59 | 75 |
| Revenue growth | — | 70.8% | 156.9% | 291.5% | 11.9% | 32.0% | 26.9% |
| Gross profit | — | 4 | 10 | −8 | 2 | 14 | 4 |
| Research and development | 46 | 63 | 135 | 156 | 241 | 314 | 475 |
| Operating income | −62 | −85 | −183 | −246 | −350 | −479 | −648 |
| Net income | −62 | −87 | −186 | −240 | −328 | −464 | −645 |
| Diluted EPS (US$) | −2.87 | −3.99 | −1.49 | −1.36 | −1.58 | −1.69 | −1.44 |
| Diluted shares (millions) | 22 | 22 | 125 | 176 | 208 | 274 | 447 |
| Cash flow | |||||||
| Cash from operations | −57 | −45 | −159 | −84 | −288 | −359 | −372 |
| Capital expenditure | 4 | 6 | 40 | 37 | 12 | 14 | 6 |
| Free cash flow | −61 | −51 | −198 | −121 | −300 | −373 | −378 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 3 | 0 | 0 | 2 | 277 | 0 |
| Stock-based compensation | 1 | 4 | 15 | 28 | 54 | 82 | 111 |
| Balance sheet at fiscal year end | |||||||
| Cash and short-term investments | 75 | 262 | 517 | 550 | 392 | 594 | 743 |
| Debt incl. finance leases | — | 12 | 1 | 1 | 1 | 27 | 19 |
| Total assets | — | 299 | 610 | 701 | 654 | 1,449 | 1,474 |
| Total liabilities | — | 57 | 67 | 216 | 190 | 414 | 343 |
| Shareholders' equity | −124 | −206 | 543 | 486 | 463 | 1,035 | 1,131 |
| Margins and ratios | |||||||
| Gross margin | — | 100.0% | 100.0% | −21.2% | 4.5% | 23.1% | 5.0% |
| Operating margin | −2,692.6% | −2,135.7% | −1,795.8% | −616.7% | −785.3% | −814.1% | −867.9% |
| Net margin | −2,668.3% | −2,196.0% | −1,832.2% | −601.0% | −736.0% | −788.0% | −863.4% |
| Free cash flow margin | −2,628.4% | −1,293.0% | −1,949.4% | −302.6% | −672.4% | −633.7% | −506.5% |
| Rule of 40 (growth + FCF margin) | — | −1,222.2% | −1,792.5% | −11.2% | −660.5% | −601.7% | −479.6% |
| Return on capital | — | — | — | — | — | −139.9% | −117.2% |
| Return on equity | — | — | −110.8% | −46.6% | −69.1% | −61.9% | −59.5% |
| Return on assets | — | — | −41.0% | −36.5% | −48.4% | −44.1% | −44.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — |